Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) | Piclidenoson (CF101) | Glaucoma | Phase 2 | Trial Discontinued | Oral | Opthalmic |
| Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) | Piclidenoson | Lowe Syndrome | Phase 2 | Enrollment Initiation | Oral | Genetic Disorder |
| Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) | Namodenoson - (CF102-222PC) | Pancreatic Cancer | Phase 2a | Ongoing | Oral | Oncology |
| Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) | Piclidenoson (CF101) | Pancreatic cancer | Phase 2 | Ongoing | Oral | Oncology |
| Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) | Namodenoson (CF102) | Metabolic dysfunction-associated steatohepatitis (MASH) | Phase 2b | IND Clearance | Oral | Gastroenterology |
| Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) | Piclidenoson - (COMFORT) | Psoriasis | Phase 3 | Enrollment Initiation | Oral | Immunology |
| Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) | Piclidenoson (CF101) | Rheumatoid arthritis | Phase 3 | Trial Discontinued | Oral | Immunology: Anti-TNF |
| Can-Fite Biopharma Ltd American Depositary Shares each representing two (2) | Namodenoson (CF102) | Advanced liver cancer, hepatocellular carcinoma | Phase 3 | Data Released | Oral | Oncology |
